Separate indirect from direct evidence (SIDE) using back-calculation method

Common effects model: 

              comparison k prop  nma direct indir. RoR z p-value
      lasmiditan:placebo 4 1.00 1.05   1.05      .   . .       .
  lasmiditan:rizatriptan 0    0 1.11      .   1.11   . .       .
  lasmiditan:sumatriptan 0    0 0.97      .   0.97   . .       .
     rizatriptan:placebo 1 1.00 0.95   0.95      .   . .       .
     sumatriptan:placebo 1 1.00 1.08   1.08      .   . .       .
 rizatriptan:sumatriptan 0    0 0.87      .   0.87   . .       .

Random effects model: 

              comparison k prop  nma direct indir. RoR z p-value
      lasmiditan:placebo 4 1.00 1.05   1.05      .   . .       .
  lasmiditan:rizatriptan 0    0 1.11      .   1.11   . .       .
  lasmiditan:sumatriptan 0    0 0.97      .   0.97   . .       .
     rizatriptan:placebo 1 1.00 0.95   0.95      .   . .       .
     sumatriptan:placebo 1 1.00 1.08   1.08      .   . .       .
 rizatriptan:sumatriptan 0    0 0.87      .   0.87   . .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)

Percent of comparisons where there is some evidence (p-value<0.05) of disagreement between direct and indirect sources: NaN (0 out of 0 comparisons).

File created on 2023-05-26.
